HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA re-targets final sunscreen rule for May

This article was originally published in The Rose Sheet

Executive Summary

According to Department of Health and Human Services' Dec. 7 semi-annual agenda, FDA aims to publish a final monograph for OTC sunscreen products in May. The agency has missed its target before, shooting for September in its summer 2009 agenda (1"The Rose Sheet" June 1, 2009). The final version of the monograph - which would address requirements for UVA protection - initially emerged in 1999 but has been consistently delayed. "FDA believes it is important to public health that we issue a final rule for OTC sunscreens as soon as possible," an FDA spokeswoman wrote in a March 17 e-mail to "The Rose Sheet." The agency is likely to take fire if another summer passes without formal protection standards for sunscreen manufacturers (2"The Rose Sheet" Nov. 24, 2008, In Brief)

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016805

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel